Promising Developments and Strategic Advancements Support Buy Rating for Ocular Therapeutix

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix and keeping the price target at $15.00.

Yi Chen’s rating is based on several promising developments for Ocular Therapeutix. The company has secured a Special Protocol Assessment (SPA) agreement with the FDA for its registrational trial design in non-proliferative diabetic retinopathy (NPDR), which provides a clear regulatory path forward. In previous trials, AXPAXLI demonstrated significant efficacy by preventing disease progression in NPDR patients, highlighting its potential as a once-a-year treatment option that could shift the current treatment paradigm.
Additionally, Ocular Therapeutix is making progress with its Phase 3 SOL-1 trial for wet age-related macular degeneration (AMD), with topline results expected in the first quarter of 2026. The company has also completed enrollment for the SOL-R trial and streamlined rescue criteria, aligning them with real-world practices, which could enhance market adoption if approved. These strategic advancements and the potential market impact of AXPAXLI support Yi Chen’s Buy rating and the $15 price target for the stock.